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Abstract
Endometrial carcinoma (EC) molecular classification based on four molecular subclasses identified in The Cancer
Genome Atlas (TCGA) has gained relevance in recent years due to its prognostic utility and potential to predict
benefit from adjuvant treatment. While most ECs can be classified based on a single classifier (POLE exonuclease
domain mutations – POLEmut, MMR deficiency – MMRd, p53 abnormal – p53abn), a small but clinically relevant
group of tumours harbour more than one molecular classifying feature and are referred to as ‘multiple-classifier’
ECs. We aimed to describe the clinicopathological and molecular features of multiple-classifier ECs with abnormal
p53 (p53abn). Within a cohort of 3518 molecularly profiled ECs, 107 (3%) tumours displayed p53abn in addition
to another classifier(s), including 64 with MMRd (MMRd–p53abn), 31 with POLEmut (POLEmut–p53abn), and
12 with all three aberrations (MMRd–POLEmut–p53abn). MMRd–p53abn ECs and POLEmut–p53abn ECs were
mostly grade 3 endometrioid ECs, early stage, and frequently showed morphological features characteristic of
MMRd or POLEmut ECs. 18/28 (60%) MMRd–p53abn ECs and 7/15 (46.7%) POLEmut–p53abn ECs showed
subclonal p53 overexpression, suggesting that TP53 mutation was a secondary event acquired during tumour
progression. Hierarchical clustering of TCGA ECs by single nucleotide variant (SNV) type and somatic copy number
alterations (SCNAs) revealed that MMRd–p53abn tumours mostly clustered with single-classifier MMRd tumours
(20/23) rather than single-classifier p53abn tumours (3/23), while POLEmut–p53abn tumours mostly clustered
with single-classifier POLEmut tumours (12/13) and seldom with single-classifier p53abn tumours (1/13) (both
p≤ 0.001, chi-squared test). Finally, the clinical outcome of patients with MMRd–p53abn and POLEmut–p53abn
ECs [stage I 5-year recurrence-free survival (RFS) of 92.2% and 94.1%, respectively] was significantly different
from single-classifier p53abn EC (stage I RFS 70.8%, p= 0.024 and p= 0.050, respectively). Our results support
the classification of MMRd–p53abn EC as MMRd and POLEmut–p53abn EC as POLEmut.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Of the many advances in the field of endometrial cancer
(EC) during the last decade, perhaps the one with most
impact is the molecular classification proposed by The
Cancer Genome Atlas (TCGA) [1], which has gained
prominence in recent years [2]. This classifies ECs
into four molecular subtypes – POLE/ultramutated
(POLE), microsatellite instability-high/hypermutated
(MSI), somatic copy-number alteration high/serous-like
(SCNA-high), and somatic copy-number alteration low
(SCNA-low) – with significantly different prognoses
[3], and thus of potential clinical relevance. For example,
the favourable outcome of POLE (exonuclease domain)
mutant EC, independent of adjuvant treatment [4], has
led to proposals to de-escalate post-operative therapy in
this subgroup [4]. In contrast, the consistently poor clin-
ical outcome of patients with SCNA-high (serous-like)
ECs suggests that intensification of adjuvant treatment
may be worthwhile. The reported response of MSI
tumours to immune checkpoint inhibitors [5,6], as well
as the possibility of a better response to adjuvant radio-
therapy [7], also opens new treatment opportunities for
this group of patients. A randomised controlled clinical
trial (PORTEC4a [8]) is currently testing the added
value of integrating this molecular approach into risk
assessment, to individualise adjuvant treatment and
reduce over- and under-treatment in patients [9].
One important contributor to the impact and rapidly
increasing adoption of the TCGA classifier is the
relative ease in which subgroups analogous to those
originally described can be identified by techniques in
routine clinical practice [9–14]. ECs analogous to the
SCNA-high subclass can be identified by p53 immuno-
histochemistry (p53abn EC) [15], the MSI subclass
by immunohistochemistry for MMR proteins (MMRd
EC), and the POLE subclass by targeted sequencing
of the POLE exonuclease domain (POLEmut EC) (the
latter being the most difficult to implement in routine
practice). Tumours lacking these three prior features
are classified as p53 wild-type (p53wt EC) [11] or no
specific molecular profile subtype (NSMP EC) [10],
analogous to the SCNA-low subclass.
Using this surrogate marker approach, most ECs can
be classified into a single molecular class (henceforward
referred to as ‘single-classifier’ ECs). However, 3–6%
of tumours have more than one molecular classifying
feature (hereafter referred to as ‘multiple-classifier’
ECs) [9–12], and include those with combined
POLE exonuclease domain mutation (EDM) and
abnormal p53 (POLEmut–p53abn), combined DNA
mismatch repair deficiency (MMRd) and abnormal
p53 (MMRd–p53abn), combined MMRd and POLE
EDM (MMRd–POLEmut), and all three defects
(MMRd–POLEmut–p53abn) [9–12]. There is cur-
rently no consensus on how these tumours should be
classified or treated; some studies have excluded them
from further analysis [10], while others have allocated
them to one of the four subtypes [11] without detailing
their clinicopathological or molecular features. Con-
sequently, the biology and prognostic significance of
multiple-classifier ECs are unclear, and how they should
be managed is unanswered. This creates an important
problem for tumours that carry opposite features, as one
may favour treatment de-escalation (POLEmut) and the
other intensified treatment (p53abn).
In this study, we aimed to perform a comprehensive
analysis of the clinical, morphological, and molecular
characteristics of EC with abnormal p53 immunos-
taining and/or TP53 mutation in combination with
POLEmut and/or MMRd in order to inform clinical
management of these multiple-classifier ECs.
Materials and methods
Patient and tissue selection
Patient identity was protected by study-specific patient
numbers. Informed consent and ethical approval were
obtained according to the local protocol in each partici-
pating centre.
We obtained patient data and tumour tissue from ECs
with more than one classifying feature (a pathogenic
POLE exonuclease domain variant, MMR protein loss
of expression or p53 abnormal expression) from pre-
viously published datasets [1,10,12,13,16,17]. A total
of 2988 ECs had been molecularly classified in pre-
vious studies [10,12,13,16,17], in which MMR and
p53 status were determined by immunohistochemistry
(IHC) and POLE variants by Sanger sequencing or
NGS of the complete exonuclease domain (exons 9–14)
or targeted sequencing of exons 9, 13, and 14. For
this current study, all POLE variants were reviewed
and tumours were excluded when the POLE variant
was not considered pathogenic following the recom-
mended approach presented by León-Castillo et al [18].
Additionally, following the criteria mentioned previ-
ously, four tumours reported as having all three molec-
ular features (POLEmut–MMRd–p53abn) but with a
non-pathogenic POLE EDM based on review were clas-
sified as MMRd–p53abn ECs. ECs with MMR loss and
a pathogenic POLE variant (MMRd–POLEmut ECs)
were excluded from this study, as they are described by
León-Castillo et al [18]. Clinical follow-up and, when
available, slides were centrally collected for further anal-
yses. Follow-up data were provided by each centre in an
anonymised dataset and datasets were combined into a
final password-protected database.
Our study cohort was further extended by 530 TCGA
ECs in which a combination of a pathogenic POLE
EDM, a TP53 variant (excluding TP53 variants clas-
sified as benign by SIFT or neutral by VEP), and/or
MSI-H (based on Bethesda protocol classification [19]
was obtained from the Genome Data Analysis Center
(GDAC) (available at http://www.broadinstitute.org/
cancer/cga). TP53 mutations were assessed using the
public databases COSMIC [20], ClinVar [21], and IARC
TP53 mutations database [22], as well as the in silico
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020
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tools SIFT [23] and PolyPhen [24]; only mutations
classified as (likely) pathogenic or variants of unknown
significance (VUS) were included in the study. This
resulted in a final study cohort of 3518 molecularly
profiled ECs.
Scoring MMR and p53 IHC
As multiple-classifier ECs are identified by IHC,
we re-evaluated or restained tumours with available
unstained slides to exclude potential misinterpretation
in the original study. Unstained sections were stained for
either two (PMS2 and MSH6) or four mismatch repair
proteins (MLH1, PMS2, MSH2, and MSH6) dependent
on slide availability [MLH1 (ES05, 1:100; Agilent
DAKO, Amstelveen, North Holland, The Netherlands),
PMS2 (EP51, 1:50; Agilent DAKO), MSH2 (FE11,
1:200; Agilent DAKO), and MSH6 (EPR 3945, 1:800;
GeneTex, Irvine, CA, USA)] and p53 (DO-7, 1:200;
Agilent DAKO).
MMRd was defined as loss of MMR nuclear staining,
for at least one MMR protein, with positive inter-
nal control. Subclonal loss of MMR expression [25]
was defined as abrupt and complete regional loss of
expression of an MMR protein with intervening stromal
positivity serving as an internal control in the regions of
absent tumour cell staining. Cases with heterogeneous
or non-abrupt patchy staining thought to be a result of
sub-optimal pre-analytic handling or those with absent
internal control staining were not considered MMRd.
An abnormal/mutant p53 IHC stain was defined as
strong nuclear expression in over 75% of the tumour
cells (overexpression), complete loss of nuclear stain
in the presence of internal control staining (complete
absence), or cytoplasmic staining (cytoplasmic), fol-
lowing scoring described by Singh et al [15]. Subclonal
abnormal p53 IHC staining was defined as abrupt and
complete regional abnormal p53 expression, in which
the subclonal region was at least 10% of the total tumour
volume. If the p53 IHC staining pattern could not be
classified into one of the previously mentioned patterns
(inconclusive p53 stain), TP53 mutational status was
used for molecular profiling through Sanger sequencing
of exons 5–8.
Histopathological review
Tumours with at least one haematoxylin–eosin (H&E)
slide available were selected for histological review,
blinded for molecular classification, by one patholo-
gist (AL, TB, BG or RS). This review consisted of
scoring for each case predefined histological features:
hobnailing, slit-like spaces, papillary growth, squamous
metaplasia, tumour intraepithelial lymphocytes (TILs),
peritumoural lymphocytes, solid growth greater than
50%, and the presence of tumour giant cells. For the
purpose of this study, we did not reassess tumour
histotype. Type of myometrial invasion and presence
of lymphovascular space invasion (LVSI) were also
annotated.
Evaluation of somatic nucleotide and copy number
variation in TCGA ECs
Somatic mutations were classified into the 96 cate-
gories described byAlexandrov et al [26]. Distancemet-
rics for the difference between pairs of samples were
generated using the mutational changes (1 – cosine
similarity/2) or the proportion of genome that had a
copy number change (both of these range between 0
and 1). These distances were combined into a single
metric using Euclidean distance. Individual and com-
bined metrics were used to cluster the samples and
plot a heatmap using the function heatmap.2 from
the package ‘gplots’ to visualise similarity between
samples.
Statistical analysis
We assessed 5-year recurrence-free survival (RFS) and
5-year overall survival (OS) comparing Kaplan–Meier
curves with the log-rank test. Follow-up time was calcu-
lated with the reverse Kaplan–Meier method. We used
Mann–Whitney tests to compare non-parametric
continuous variables; categorical variables were
assessed with Fisher’s exact test or the chi-squared
test. Two-sided P value less than 0.05 was considered
significant.
Results
Identification and clinicopathological
characteristics of multiple-classifier ECs
Our initial cohort comprised 3518 tumours, 3353
being classified to a single molecular subtype. Of
the remaining 167 tumours, 30 were classified as
MMRd–POLEmut ECs and will be reported sepa-
rately (León-Castillo et al [18]), leaving 138 tumours
(3.9%) that were assigned a provisional status of
multiple-classifier with abnormal p53 (mutant p53
expression by IHC or a mutation in TP53). Stringent
quality control including central pathological review
resulted in the exclusion of 35 of these ECs for the
following reasons: (1) reassignment of p53 immunos-
taining from mutant to wild-type pattern (n= 27, 21
being initially evaluated using tissue microarrays);
(2) non-pathogenic POLE variant (n= 3); and (3)
lack of evidence of MMRd on IHC review (n= 1)
(Figure 1). The remaining 107 tumours (3% of total)
met the inclusion criteria and were used for subsequent
analyses.
The clinicopathological characteristics of the patients
with these 104 ECs are shown in Table 1 [27,28]. The
mean age was 62 (range 35–87) years. The FIGO 2009
stage was as follows: 80 (76.9%) stage I and 24 (23.1%)
stage II–IV. The most common combination of clas-
sifiers was MMRd–p53abn (64; 1.8% of 3518), fol-
lowed by POLEmut–p53abn (31; 0.9% of 3518) and
MMRd–POLEmut–p53abn (12; 0.3% of 3518).
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020
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Figure 1. Flow chart of sample analysis. POLEmut–MMRd ECs are reported separately in León-Castillo et al [18].
DNA mismatch repair-deficient, p53 abnormal
(MMRd–p53abn) ECs
From the total study population, 64 tumours had both
MMRd/MSI and abnormal p53 (MMRd–p53abn)
(Table 1). Of these, 40 (62.5%) were classified based
on MMR protein expression, with an unusually high
number of ECs (n= 25, 62.5%) presenting with loss of
MSH6 +/−MSH2, or single PMS2 loss [25]. The mean
patient age in this subgroup was 62 years. Most tumours
were endometrioid (46/64, 71.9%), with 65.2% being
grade 3. 76.7% (49/64) of these patients had early-stage
ECs (stage I–II). Central histological review was
possible in 54 ECs (median of two slides per case,
range 1–17) (supplementary material, Table S1) and
typically revealed a dense lymphoid infiltrate (peritu-
moural lymphocytes in 59.3% and tumour-infiltrating
lymphocytes in 42.6% of tumours). LVSI was observed
in 33.3% of tumours. Solid growth (≥ 50% of the
tumour) was present in 24 (44.4%) ECs, and squamous
metaplasia was identified in 13 (24.1%). Hobnailing,
slit-like spaces or papillary growth was present in
eight (14.8%), 12 (22.2%), and 14 (25.9%) tumours,
respectively.
p53 IHC was available for central review in 28 of
the 64MMRd–p53abn tumours. Nine (30%) showed
p53 overexpression, while one tumour had an incon-
clusive staining pattern in combination with a con-
firmed pathogenic TP53 mutation. Interestingly, the
remaining 18 tumours (60%) showed abrupt strong p53
nuclear overexpression (> 75% of all tumour nuclei) in
a well-defined area (at least 10% of tumour volume), a
pattern defined as subclonal p53abn staining (Figure 2).
To further characterise the group of MMRd–p53abn
ECs, we used sequencing data from the TCGA
study, comparing analogous tumours with combined
microsatellite instability and TP53 mutation (MMRd–
p53abn EC, n= 23) with those with one of these defects
in isolation (henceforth referred to as single-classifier
MMRd EC if microsatellite-unstable and single-
classifier p53abn EC if TP53-mutant). Fifteen (65%)
MMRd–p53abn ECs had a (likely) pathogenic TP53
mutation and eight (35%) had a TP53VUS. Preliminary
analysis revealed a significantly higher frequency of
multiple TP53 mutations in MMRd–p53abn tumours
when compared with single-classifier p53abn (i.e.
lacking POLE mutation or MSI-H) ECs (36.4% versus
2.7%, p< 0.001, Fisher’s exact test). To further define
the molecular characteristics of MMRd–p53abn ECs,
we performed hierarchical clustering of TCGA ECs
according to the proportion of SNVs of each trinu-
cleotide context and SCNA burden (see the Materials
and methods section), revealing that MMRd–p53abn
ECs clustered mostly with single-classifier MMRd
tumours (which are typically SCNA-low) rather than
with single-classifier p53abn ECs (20/23 versus 3/23,
respectively; p≤ 0.001) (Figure 2). Similar results were
obtained when analysing individually SNVs and SCNA
(supplementary material, Figure S1).
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020
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Table 1. Clinicopathological characteristics of multiple-classifier EC with abnormal p53
Total
n=107 (%)
MMRd–
p53abn EC
n= 64 (%)
POLEmut–
p53abn EC
n= 31 (%)
MMRd–
POLEmut–
p53abn EC
n= 12 (%)
Age, years
Mean [range] 61.6 [35–87] 61.7 [35–87] 62.1 [50–83] 59.9 [47–74]
< 60 51 (47.7) 28 (43.8) 16 (51.6) 7 (58.3)
60–70 33 (30.8) 22 (34.4) 8 (25.8) 3 (25.0)
> 70 22 (20.6) 14 (21.9) 6 (19.4) 2 (16.7)
Missing 1 (0.9) 0 (0) 1 (3.2) 0 (0)
Stage
IA 41 (38.3) 25 (39.1) 9 (29) 7 (58.3)
IB 41 (38.3) 22 (34.4) 15 (48.4) 4 (33.3)
II 3 (2.8) 2 (3.1) 1 (3.2) 0 (0)
III 16 (15) 11 (17.2) 4 (12.9) 1 (8.3)
IV 6 (5.6) 4 (6.3) 2 (6.5) 0 (0)
Histology
Endometrioid 77 (72) 46 (71.9) 22 (71) 9 (75.0)
Serous 9 (8.4) 6 (9.4) 2 (6.5) 1 (8.3)
Mixed 16 (15) 8 (12.5) 6 (19.4) 2 (16.7)
Clear cell 3 (2.8) 2 (3.1) 1 (3.2) 0 (0)
Undifferentiated 2 (1.9) 2 (3.1) 0 (0) 0 (0)
Grade
1–2 25 (23.4) 16 (25) 7 (22.6) 2 (16.7)
3 82 (76.6) 48 (75) 24 (77.4) 10 (83.3)
Myometrium invasion
Intramucosal 4 (3.7) 2 (3.1) 0 (0) 2 (16.7)
< 50% 45 (42.1) 28 (43.8) 11 (35.5) 6 (50.0)
> 50% 53 (49.5) 31 (48.4) 19 (61.3) 4 (33.3)
Missing 5 (4.7) 3 (4.7) 1 (3.2) 0 (0)
LVSI
Absent 44 (41.1) 22 (34.4) 15 (48.4) 7 (58.3)
Present 32 (29.9) 23 (35.9) 5 (16.1) 4 (33.3)
Missing 31 (29.0) 19 (29.7) 11 (35.5) 1 (8.3)
Treatment
Radiotherapy 18 (16.8) 12 (18.8) 5 (16.1) 1 (8.3)
Chemotherapy 9 (8.4) 4 (6.3) 4 (12.9) 1 (8.3)
Radiochemotherapy 10 (9.3) 7 (10.9) 3 (9.7) 0 (0)
None 15 (14.0) 9 (14.1) 4 (12.9) 2 (16.7)
Missing 55 (51.4) 32 (50) 15 (48.4) 8 (66.7)
Risk classification (ESMO clinical practice guidelines, 2013 [27])
Low risk 9 (8.4) 6 (9.4) 3 (9.7) 0 (0)
Intermediate risk 31 (29.0) 16 (25) 8 (25.8) 7 (58.3)
High risk 51 (47.7) 30 (46.9) 17 (54.8) 4 (33.3)
Advanced stage I 13 (12.1) 10 (15.6) 2 (6.5) 1 (8.3)
Metastatic 3 (2.8) 2 (3.1) 1 (3.2) 0 (0)
Risk classification (ESMO–ESTRO–ESGO clinical practice guidelines, 2016 [28])
Low risk 4 (3.7) 2 (3.1) 2 (6.5) 1 (8.3)
Intermediate 11 (10.3) 7 (10.9) 3 (9.7) 0 (0)
High–intermediate 22 (20.6) 11 (17.2) 5 (16.1) 6 (50)
High 59 (55.1) 37 (57.8) 17 (54.8) 5 (41.7)
Advanced or metastatic 6 (5.6) 4 (6.3) 2 (6.5) 0 (0)
Not assessable 5 (4.7) 3 (4.7) 2 (6.5) 0 (0)
POLE-mutant, p53-abnormal (POLEmut–p53abn)
ECs
A total of 31 ECs (0.9%) had both a POLE mutation
and abnormal p53 (POLEmut–p53abn) (Table 1). In all
of these POLEmut–p53abn ECs, the POLE variant was
a known pathogenic mutation including p.Pro286Arg
(16), p.Val411Leu (10), Ala456Pro (3), p.Ser459Phe
(1), and p.Pro436Arg (1), as described by León-Castillo
et al [18]. Patients with POLEmut–p53abn ECs had
a mean age of 62 years. Histologically, these tumours
were most frequently grade 3 endometrioid EC (n= 15,
48.4%). Twenty-four patients had (77.4%) stage I
tumours, 1 (3.2%) had a stage II, 4 (12.9%) had stage
III, and 2 had (6,5%) stage IV tumours. Thirty cases
were available for morphological review (median two
slides available per case, range 1–15) (supplemen-
tary material, Table S1). This revealed a prominent
lymphoid infiltrate in the majority of ECs (90.9%
with peritumoural lymphocytes and 59.1% with TILs).
Tumour giant cells, previously reported in 33–40%
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020
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Figure 2. MMRd–p53abn EC IHC and molecular features. Subclonal p53 staining and loss of PMS2 are shown in A (×5 original
magnification). Percentage of cases with subclonal and diffuse abnormal p53 staining patterns is depicted in B. (C) Heatmap showing
hierarchical clustering of MMRd–p53abn, single-classifier MMRd, and single-classifier p53abn ECs in TCGA, based on mutational changes
and copy number changes. Individual similarity metrics for copy number and mutational changes were combined using Euclidean distance.
Patients were classified in groups based on MMRd–p53abn (brown), single-classifier MMRd (green), and single-classifier p53abn (red).
Samples were ordered based on hierarchical clustering.
of POLE-mutant single-classifier ECs [29,30], were
observed in 12 (40%) tumours and substantial LVSI
was present in 10%. Solid growth ≥ 50% was identified
in 16 cancers (53.3%) and squamous metaplasia in 4
(13.3%). Hobnailing was observed in four (13.3%),
slit-like spaces in six (20%), and papillary growth in
four (13.3%) tumours.
Central review of p53 immunostaining was possible
in 15 tumours. Six (37.5%) had diffuse overexpression
of p53; one showed complete loss of p53 expression;
and one had inconclusive p53 staining with a confirmed
TP53 mutation. Intriguingly, similar to our results
in MMRd–p53 multiple-classifier ECs, subclonal
abnormal p53 staining (subclonal overexpression) was
frequent (n= 7, 46.7%) (Figure 3).
We used the TCGA EC cohort to compare the 13
ECs with combined POLE mutation and TP53mutation
(POLEmut–p53abn) with tumours with either defect
alone (single-classifier POLEmut and single-classifier
p53abn EC). Eight (62%) POLEmut–p53abn ECs
had at least one TP53 (likely) pathogenic mutation,
the remaining five (38%) having at least one VUS.
POLEmut–p53abn ECs more frequently had multiple
TP53 mutations when compared with single-classifier
p53abn tumours (75% versus 2.7%, p< 0.001, Fisher’s
exact test). Additionally, known TP53 mutational
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020
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Figure 3. POLEmut–p53abn EC IHC and molecular features. Subclonal p53 staining and H&E stain of a POLEmut–p53abn EC are shown
in A (×5 original magnification). Percentage of cases with subclonal and diffuse abnormal p53 staining patterns is depicted in B. (C)
Heatmap showing hierarchical clustering of POLEmut–p53abn, single-classifier POLEmut, and single-classifier p53abn ECs in TCGA, based
on mutational changes and copy number changes. Individual similarity metrics for copy number and mutational changes were combined
using Euclidean distance. Patients were classified in groups based on POLEmut–p53abn (pink), single-classifier POLEmut (blue), and
single-classifier p53abn (red). Samples were ordered based on hierarchical clustering.
hot-spot codons Arg 175, Gly 245, Arg 248, Arg 249,
Arg 273, and Arg 282 [31] were seldom mutated in
POLEmut–p53abn ECs, in contrast to single-classifier
TP53mut ECs where these alterations were common,
although this difference was not statistically significant
[1/12 (8%) versus 57/184 (31.5%); p= 0.11].
Further analysis of TP53 mutations by trinucleotide
context demonstrated that TCT>TAT alterations
(characteristic of POLEmut carcinomas [26,32])
were uncommon in POLEmut–p53abn ECs (4.2%)
and absent in single-classifier p53abn ECs (0/116)
(p= 0.31). However, TCG>TTG substitutions (also
substantially enriched in POLEmut carcinomas [32])
accounted for 6/24 (25%) of the TP53 variants in
POLEmut–p53abn in contrast to single-classifier
p53abn ECs in which these alterations did not occur
(p≤ 0.001).
Hierarchical clustering of ECs by SNV and SCNA
proportions revealed that 12 of 13 POLEmut–p53abn
ECs clustered with single-classifier POLE-mutant ECs,
while a single case clustered with the single-classifier
p53abn tumours (p≤ 0.001, chi-squared test) (Figure 3).
Separate analysis of SNV and SCNAs rendered similar
results (supplementary material, Figure S2).
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POLE-mutant, DNA mismatch repair-deficient
p53-abnormal (MMRd–POLEmut–p53abn) ECs
From our pooled cohort, 12 ECs (0.3%) demon-
strated concomitant pathogenic POLE EDM, mismatch
repair deficiency, and abnormal p53 (MMRd–
POLEmut–p53abn ECs) (Table 1). All cancers had
a known pathogenic POLE mutation, as described by
León-Castillo et al [18], including p.Pro286Arg (1),
p.Val411Leu (4), p.Ser297Phe (2), p.Ser459Phe (1),
p.Phe367Ser (2), p.Leu424Ile (1), and p.Met295Arg
(1). These patients had a mean age of 60 years and
presented with early-stage tumours (58.3% stage IA
and 33.3% stage IB). Most MMRd–POLEmut–p53abn
ECs were endometrioid (n= 9, 75%), whereas two
were classified as mixed ECs (serous and endometrioid)
and one as serous EC. Eleven tumours were available
for morphological review (supplementary material,
Table S1). An abundant lymphoid infiltrate was present
in these tumours [8 (72.7%) had prominent TILs and 10
(90.9%) peritumoural lymphocytes]. Hobnailing was
observed in one (9.1%) tumour, slit-like spaces were
present in two (18.2%), and three (27.3%) had papillary
growth. In 4/11 of these MMRd–POLEmut–p53abn
ECs, we were able to re-evaluate p53 and MMR IHC.
All four displayed subclonal p53abn expression and two
of them additionally showed subclonal loss of MLH1
with concomitant loss of PMS2 expression.
We further analysed the seven MMRd–POLEmut–
p53abn ECs available in the TCGA. Five tumours had a
TP53 (likely) pathogenic mutation and two had a VUS.
Hierarchical clustering based on SNV and SCNA pro-
portions (supplementary material, Figure S3) showed
five tumours clustering with single-classifier POLEmut
ECs, two with single-classifier MMRd ECs, and none
with single-classifier p53abn ECs. Of note, the two ECs
that clusteredwith single-classifierMMRd cancers had a
V411L and L424I POLE variant, respectively, with low
C>A substitutions and high indels [18] and pathogenic
TP53 mutations.
The limited number of MMRd–POLEmut–p53abn
ECs with available clinical data (n= 9) did not allow for
survival analysis.
Clinical outcome of multiple-classifier ECs versus
single-classifier ECs
Finally, we investigated the outcome of MMRd–p53abn
ECs and POLEmut–p53abn ECs in the pooled
study population (supplementary material, Table S2).
Fourty-four MMRd–p53abn ECs were available for
survival analysis. Patients had a 5-year RFS and OS of
83.4% and 82%, respectively (supplementary material,
Figure S4). RFS and OS could be analysed for 23
patients with POLEmut–p53abn ECs. The survival
analysis revealed that these ECs were associated with a
favourable outcomewith a 90.9% 5-year RFS and 5-year
OS of 95.2% (supplementary material, Figure S4).
We further analysed the clinical outcome of
multiple-classifier ECs by comparing their 5-year
Figure 4. Survival analysis of multiple-classifier EC compared with
single-classifier p53abn EC. Five-year recurrence-free survival
analysis of stage I MMRd–p53abn EC (A) and POLEmut–p53abn
EC (B) compared with single-classifier p53abn EC. Two-sided P val-
ues were obtained from log-rank testing. Patients were classified
based on POLEmut–p53abn (pink), MMRd–p53abn (brown), and
single-subtype p53abn (red).
RFS with single-classifier p53abn ECs. For this pur-
pose, we used a cohort of 187 single-classifier p53abn
ECs described previously [12,13]. These patients had
a lower proportion of stage I disease (93, 49.7%)
compared with MMRd–p53abn ECs (31, 70.5%) and
POLEmut–p53abn ECs (19, 82.6%). Due to the dif-
ferences in stage distribution, only stage I ECs were
analysed. Thus, patients with stage I single-classifier
p53abn ECs had a 5-year RFS of 70.8%, while those
with stage I MMRd–p53abn ECs (n= 31) had an
RFS of 92.2% (p= 0.024) and patients with stage I
POLEmut–p53abn EC (n= 19) showed an RFS of
94.1% (p= 0.050) (Figure 4).
Discussion
The molecular EC classification developed by TCGA
has the potential to become the new standard in
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diagnostic pathology. Together with stage, the molec-
ular subtype of EC provides powerful prognostic
information; unlike stage, this information can be very
accurately determined at the time of initial biopsy [33].
When using the surrogate approach to determine the
four molecular subtypes (POLEmut, MMRd, p53abn,
and NSMP EC), a small but clinically relevant number
of ECs (3–5%) have been unclassifiable due to the
presence of more than one molecular classifying fea-
ture. These so-called ‘multiple-classifier’ ECs create a
hurdle in the application of the molecular EC classi-
fication in practice, as it is not immediately apparent
how these should be classified/treated. This issue is
particularly relevant for the co-occurrence of abnormal
p53 IHC in the context of MMRd or POLEmut, as
these features, when present singly, are associated with
opposing clinical outcomes. The present study is the
first to provide an extensive characterisation of these
uncommon multiple-classifier ECs and by doing so,
provides guidance on how these should be interpreted.
The molecular landscape of single-classifier
POLEmut EC, p53abn EC or MMRd EC cases is
considered to be shaped by their driver alterations,
being POLE EDM, TP53 mutation or MMR defi-
ciency. Interestingly, we observed similar mutational
changes and SCNA between MMRd–p53abn EC and
POLEmut–p53abn EC with single-classifier MMRd
and POLEmut EC, respectively. This strongly sug-
gests that TP53 variants occurring in the context of an
MMRd or POLEmut EC are likely passenger events,
not affecting the molecular landscape of the tumour.
This is further supported by the phenotype of the
multiple-classifier ECs, as pathology review revealed
an enrichment for features associated with MMRd
or POLEmut EC (TILs, peritumoural lymphocytes,
squamous metaplasia) and not serous-like (p53abn)
features. Another important observation in support
of this interpretation is the unusual high frequency
(47–60%) of subclonal abnormal p53 staining in the
multiple-classifier EC. Of note, cases designated as
single-classifier p53 EC from the previously published
PORTEC-1/-2 cohorts (n= 74) did not show subclonal
expression [10]. This same observation was made
independently by Singh et al [15]. Together, these
data strongly support the interpretation that the TP53
mutation is a later event during tumour progression in
multiple-classifier EC, without affecting the molecular
landscape or the phenotype.
Multiple-classifier EC can be identified on the basis
of sequencing approaches (e.g. presence of POLE
and TP53 mutations by sequencing) or by the use
of surrogate markers (e.g. abnormal p53 IHC). By
sequencing, more TP53 mutations will be identified,
resulting in the higher number of multiple-classifiers
present in TCGA (TP53 mutational status-based) com-
pared with the cases identified using the surrogate
marker approach (p53 IHC-based) [34]. This is likely
the result of the high number of ‘non-hotspot’ TP53
mutations in POLEmut–p53abn EC compared with
single-classifier TP53mut EC, as well as the higher sen-
sitivity of sequencing approaches to identify subclonal
events (low allele frequency). These non-hotspot TP53
mutations appear to not always impact the expression
and function of p53. This is in line with Singh et al
[15], where a high proportion of cases with such a
TP53 variant and p53 wild-type staining pattern were
identified in multiple-classifier ECs.
We also describe a limited number of MMRd–
POLEmut–p53abn ECs (‘triple-classifier’). The data
available are insufficient to suggest how to treat
patients with these cancers. The presence of p53abn
subclonal staining in these cases suggests that, as in
MMRd–p53abn and POLEmut–p53abn ECs, the TP53
mutations occur as a secondary event. However, it
is difficult to assess, with the present data, whether
POLEmut or MMRd are the driving events in these can-
cers. A larger number of these triple-classifier cases will
be required to study the biological behaviour of these
ECs. Until then, considering the results reported by
León-Castillo et al [18] on MMRd–POLEmut ECs and
the present study, we suggest that these triple-classifiers
be classified as POLEmut ECs if they have a pathogenic
POLE EDM based on whole-exome sequencing (WES)
data or, in the case of absence of WES data, if the
POLE EDM corresponds to one of the 11 pathogenic
mutations described by León-Castillo et al [18]. In
tumours in which the triple-classifier ECs carry a POLE
EDM that does not comply with the previous criteria,
we recommend that they be classified as MMRd ECs,
as discussed in depth by León-Castillo et al [18].
Finally, we addressed the question of whether the
biological behaviour of POLEmut and MMRd ECs is
impacted by the presence of abnormal (subclonal) p53
expression. Although the number of cases is limited,
the clinical outcomes of MMRd–p53abn ECs and
POLEmut–p53abn ECs are strikingly different from
what would be expected in single-classifier p53abn
(SCNA-high/serous-like) ECs [1,9–14]. This supports
the concept that passenger events do not affect biolog-
ical behaviour. For clinical management, this means
that the presence of TP53 mutations in the context
of MMRd EC or POLEmut EC should not prompt
intensified treatment.
In addition to multiple-classifier ECs with mutant
p53 expression/TP53 mutation, a fourth group of ECs
with multiple classifying features can be encountered:
MMRd–POLEmut ECs. The genomic architecture
and clinical outcome of MMRd–POLEmut ECs dif-
fer depending on the pathogenicity of the POLE
exonuclease domain variant and the ultramutated phe-
notype it confers to the tumour [18]. Thus, the base
change and indel proportion of ECs with pathogenic
POLE EDM (as defined by the POLE score) and
MSI are similar to MSS ECs with pathogenic POLE
EDM [18]. Additionally, when examining a cohort of
MMRd ECs with pathogenic POLE EDM, although
the number of patients was limited (n= 14), a good
clinical outcome was observed (5-year RFS 92.3%),
in line with the prognosis described previously for
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single-classifier POLEmut ECs (supplementary mate-
rial, Figure S5) [9–14,18,35,36]. These findings support
the classification of tumours with a pathogenic POLE
EDM and MMRd as single-classifier POLEmut ECs.
In conclusion, this study is the first to describe
evidence in support of categorising multiple-classifier
POLEmut–p53abn EC as single-classifier POLEmut,
and MMRd–p53abn EC as single-classifier MMRd.
Although rare (∼3%), correct designation of
multiple-classifier ECs facilitates the implementa-
tion of the molecular EC classification, enabling them
to be included in future studies and, more importantly,
providing valuable information for clinicians and
patients to guide management.
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